iShares 7-10 Year Treasury Bond ETF vs Roivant Sciences Ltd. Common Shares — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.38 (market cap $41.13B), while Roivant Sciences Ltd. Common Shares trades at $35.54 (market cap $24.72B). The key difference: iShares 7-10 Year Treasury Bond ETF is the larger of the two by market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and Roivant Sciences Ltd. Common Shares for 1 Days on average.
| IEF | ROIV | |
|---|---|---|
Market Cap | $41.13B | $24.72B |
Volume | 10,340,382 | 6,279,442 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $41.81 |
52-Week Low | $88.92 | $16.04 |
Typical Hold Time | 108 Days | 1 Days |
Enterprise Value | — | $20.99B |
Signals from Pluang's Aura AI — not financial advice
IEF trades at $89.335, up 0.25% with a bearish technical signal from moving averages. The fund shows neutral oscillator readings with RSI at 52.94. Recent dividend payments of $0.31-$0.33 provide income, while bond market volatility and rising Treasury yields create headwinds. Support is clustered around $89 with resistance at $90.
The outlook remains cautious amid persistent bond market pressure. While dividend income offers stability, the bearish technical trend and macroeconomic uncertainty suggest limited near-term upside. Key risks include continued yield increases and inflation concerns that could pressure bond prices further.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →